Richard E. Gammans

Biography

 Dr. Richard E. Gammans, Sr., Ph.D., serves as Chief Operations Officer at Synereca Pharmaceuticals, Inc. Dr. Gammans serves as the President and Chief Operating Officer of Pamlico Biopharma, Inc. Dr. Gammans serves as the President and Chief Operating Officer of Otologic Pharmaceutics, Inc. He is employed at MediciNova (Europe) Limited. Dr. Gammans served as Chief Development Officer of Medicinova Inc. from May 2005 to June 12, 2009. Dr. Gammans served as Executive Vice President of Clinical Research of MediciNova Inc. from June 2004 to May 2005. Prior to joining MediciNova Inc., Dr. Gammans served as Executive Vice President of Research and Development at Aeolus Pharmaceuticals Inc. (formerly Incara Pharmaceuticals) from June 2000 to June 11, 2004. Incara Pharmaceuticals is a public biopharmaceutical company, where he was the executive officer responsible for research, development and regulatory affairs, a member of the corporate controls committee and the executive financing and business development team. From March 1994 to May 2000, he served as Senior Vice President of Clinical Research at Interneuron Pharmaceuticals, where he directed its clinical development programs in stroke and anxiety disorders. Prior to joining Interneuron, Dr. Gammans spent 14 years at Bristol-Myers Squibb, where he began as a Senior Scientist and progressed through a series of increasingly more senior positions in toxicology, pharmacokinetics and clinical pharmacology, to assume the position of Director of CNS Clinical Research and responsibility as Global Project Director for the anti-depressant, Serzone. Prior to joining Accele, Dr. Gammans held executive positions with GFI Pharmaceutical Services., Inc. Dr. Gammans held executive positions with MediciNova Pharmaceuticals, Inc. Since 2009, Dr. Gammans has been engaged in several consulting, education and public-interest activities, including service as outside reviewer of business plans for the Marine Biology and Drug Discovery Centers of Innovation, part of a $25 million economic development activity of the State of North Carolina administered by the NC Biotechnology Center (NCBC). As a corporate executive, Dr. Gammans has worked with all product development activities, including market evaluation, clinical research, biometrics, regulatory affairs and manufacturing. He has extensive experience in supporting investor relations and business development efforts and more than 30 years’ experience in all aspects of medication development and scientific support of marketed products. He has contributed to the development and regulatory approval of seven new molecular entities with over 50 national marketing authorizations in Western Europe and North America, including seven approved United States NDAs. He has key management experience in large, multi-national company, small company and start-up company environments. He served as Adjunct Associate Professor of Tufts University School of Medicine from 1994 to 2000, was a Senior Biochemist for USV Pharmaceutical Corp., and was Associate Director of Bristol Myers Co.’s Mead Johnson Pharmaceutical Division. Dr. Gammans completed an NIH postdoctoral fellowship in the University of Minnesota’s Departments of Medicinal Chemistry and Pharmacology. Dr. Gammans received his Ph.D. from the University of Georgia School of Pharmacy and holds an M.S. in Management from Purdue University’s Krannert Graduate School of Management.

Research Interest

 Business